Evidence map›Paper›PMID 42538423›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

β

Weilan Mo, Nicole A Beard, Katherine T Gillette-Browne, Karen Hay, Elizabeth Cheesman, Alexander Dashwood, Melanie Spratt, Annalese B Semmler, Yee Weng Wong, Haris Haqqani and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Weilan Mo *Cardio-Vascular Molecular & Therapeutics Translational Research Group, Northside Clinical School of Medicine, University of Queensland, The Prince Charles Hospital, Brisbane, Australia.
Nicole A Beard *Faculty of Science and Technology, University of Canberra, Bruce, ACT, 2617, Australia.
Katherine T Gillette-BrowneSchool of Clinical Sciences, Queensland University of Technology, Brisbane, Australia.
Karen HayQIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia.
Elizabeth CheesmanCardio-Vascular Molecular & Therapeutics Translational Research Group, Northside Clinical School of Medicine, University of Queensland, The Prince Charles Hospital, Brisbane, Australia.
Alexander DashwoodCardio-Vascular Molecular & Therapeutics Translational Research Group, Northside Clinical School of Medicine, University of Queensland, The Prince Charles Hospital, Brisbane, Australia.
Melanie SprattCardio-Vascular Molecular & Therapeutics Translational Research Group, Northside Clinical School of Medicine, University of Queensland, The Prince Charles Hospital, Brisbane, Australia.
Annalese B SemmlerSchool of Clinical Sciences, Queensland University of Technology, Brisbane, Australia.
Yee Weng WongCardio-Vascular Molecular & Therapeutics Translational Research Group, Northside Clinical School of Medicine, University of Queensland, The Prince Charles Hospital, Brisbane, Australia.
Haris HaqqaniCardio-Vascular Molecular & Therapeutics Translational Research Group, Northside Clinical School of Medicine, University of Queensland, The Prince Charles Hospital, Brisbane, Australia.
Derek R LaverSchool of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW, 2308, Australia.
Torsten ChristDepartment of Experimental Pharmacology and Toxicology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Kafa WalweelCardio-Vascular Molecular & Therapeutics Translational Research Group, Northside Clinical School of Medicine, University of Queensland, The Prince Charles Hospital, Brisbane, Australia. k.walweel@uq.edu.au.ORCID https://orcid.org/0000-0003-1866-5767
Peter MolenaarCardio-Vascular Molecular & Therapeutics Translational Research Group, Northside Clinical School of Medicine, University of Queensland, The Prince Charles Hospital, Brisbane, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In heart failure, β-adrenergic receptor (β-AR)-Gsα-cAMP-protein kinase A (PKA) signalling predisposes to delayed-afterdepolarisation-mediated arrhythmias. Phosphodiesterases (PDEs) hydrolyse cAMP, and PDE3 restrains β

Indexed as

ArrhythmiaHeart failurePDE3PhosphodiesterasesRyanodine receptorβ1-adrenergic receptorsβ2-adrenergic receptorsβ-Blockers

Identifiers

PMID42538423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.